Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.

Dextromethorphan (DXM) is a synthetic analog of codeine, but unlike codeine, it is not a narcotic and does not have the same potential for abuse or addiction.

FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.

On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.

The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.

Acyclovir, sold as ZOVIRAX, is a synthetic drug that inhibits herpes viruses, including HSV-1, HSV-2, and VZV, both in lab and living organisms.

Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.

Hospitalization data for darolutamide/docetaxel in metastatic prostate cancer were presented at 2024 ASCO_GU on Jan 25, comparing daro/docetaxel/ADT with placebo/docetaxel/ADT.

Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.

CELEBREX (celecoxib) is a nonsteroidal anti-inflammatory drug. Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.

Monopar Approved to Initiate Initial Human Stage 1 Study of Experimental Radiotherapeutic MNPR-101-Zr for Progressive Cancer Cases.

On January 30, 2024, Regeneron revealed plans to acquire 2seventy bio's immuno-cell therapy pipeline and related manufacturing capabilities under a new agreement.